Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$195.6M
28M shares
52-week range
$5.85 – $24.17
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.52%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.8M | $20.8M | $9.5M | $12.4M | $205.8M | $157.7M | $138.4M | $67.2M |
| Cost of revenue | $17.0M | $0 | $55.9M | $0 | $0 | $0 | $0 | $3.0M |
| Gross profit | −$1.2M | $20.8M | −$46.4M | $12.4M | $205.8M | $157.7M | $138.4M | $64.2M |
| Gross margin | -7.8% | 100.0% | -486.5% | 100.0% | 100.0% | 100.0% | 100.0% | 95.5% |
| R&D | $17.0M | $33.6M | $57.8M | $173.8M | $147.8M | $192.1M | $195.2M | $112.2M |
| Operating income | −$21.8M | −$25.5M | −$71.5M | −$202.9M | $12.2M | −$78.2M | −$95.7M | −$75.0M |
| EBITDA | −$20.7M | −$24.5M | −$70.6M | −$199.8M | $15.2M | −$24.2M | −$77.4M | −$62.8M |
| Net income | −$21.8M | −$26.0M | −$72.1M | −$203.7M | $9.3M | −$29.7M | −$80.9M | −$65.8M |
| Net margin | -138.3% | -125.0% | -756.3% | -1648.0% | 4.5% | -18.8% | -58.5% | -97.9% |
| EPS (diluted) | -2.16 | -2.13 | -3.55 | -7.74 | 0.35 | -1.12 | -3.00 | -2.40 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $16M | $-4.06 | $-4.66–$-3.70 | 8 |
| 2027 | $35M | $-3.95 | $-4.85–$-3.07 | 8 |
| 2028 | $47M | $-3.49 | $-5.00–$-2.00 | 7 |
| 2029 | $134M | $-1.84 | $-6.26–$-0.36 | 2 |
Forward consensus · source: Financial Modeling Prep
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
www.arcturusrx.comNo one on the platform currently holds ARCT.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 178,300 | $1.4M |
No one on the platform has traded ARCT yet.
| $134M |
| — |
| IMRXImmuneering Corporation | $5.05 | +6.09% | $183M | — |
| SGMTSagimet Biosciences Inc. | $7.79 | +10.34% | $254M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 1.4× sales vs its 5.1× historical median P/S.
Fair value ≈ $25.79 · price $6.82 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ARCT Microchip-Like, Parasite-Like, and 'Self-Assembling Nanotech' Structures Found Inside Pfizer COVID-19 Vaccine: Journal 'IJVTPR' Researchers publishing in the International Journal of Vaccine Theory, Practice, and Research this month have released a study featuring darkfield microscopy images of what they describe as self-assembling “parasites,” massive ribbon-like structures, compartmentalized protocells, and a rectangular embedded structure inside Pfizer COVID-19 vaccine material, arguing that the findings are consistent with advanced synthetic biological architectures. The publication comes as the CDC awards Pfizer more than $1.24 billion in contracts for more COVID shots. The new paper, “From Synthetic DNA and RNA-Based Self-Assembling Nanotechnology to Sequelae of COVID-19 Shots,” was published June 19 by independent researcher Shimon D. Yanowitz and Okinawa Christian University professor Daniel Broudy. https://jonfleetwood.substack.com/p/microchip-like-parasite-like-and
View on StockTwits ↗$ARCT Flu shots are back on the table for the military. Personally, I think that the flu shots should be up to the individual to take them or not.
View on StockTwits ↗$ARCT Pfizer, buy Arcturus. Our stuff works. A $598 per share would be great. $17 billion. Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial Without revealing specific data, Pfizer said in a Monday release that sigvotatug vedotin, which the pharma acquired through its $43 billion takeover of Seagen in 2023, did not elicit statistically significant overall survival (OS) benefits in the Phase 3 SigVie-002 study of patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). https://www.biospace.com/drug-development/pfizer-delivers-disappointing-late-stage-lung-cancer-data-for-adc-from-43b-seagen-buy
View on StockTwits ↗$ARCT tired of this grow and dip game. After the big dip I thought it will incres at least 20 bucks. But he still between 6-9 dolars for more than 9 months.. this is crazy.
View on StockTwits ↗$ARCT https://noticiasargentinas.com/sociedad/hantavirus--murio-una-mujer-que-se-encontraba-internada-en-bariloche_a6a3a6c89d3cd8e54997465d2 Maybe the Andes virus has been spreading quietly in South America for a long time
View on StockTwits ↗$ARCT LUNAR®-FLU (ARCT-2138) will save the day. At least 160 troops have been sickened and one trainee has died amid a viral flu outbreak at an Air Force base that struck less than two months after the military scrapped its flu vaccination requirements. In April, Defense Secretary Pete Hegseth said that troops would no longer need to get the annual flu shot, jettisoning a rule that had been in place since the 1950s. Now, Lackland Air Force Base in southern Texas is reported to be battling a flu outbreak at a training wing where hundreds sleep, eat and congregate in close quarters. And earlier this week, a trainee in his sixth week of basic training died after becoming sick. https://www.dailymail.com/health/article-15914055/air-force-base-flu-outbreak-vaccine-texas.html
View on StockTwits ↗$ARCT Soon for us. 𝐅𝐃𝐀 𝐩𝐚𝐧𝐞𝐥 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐬 𝐟𝐢𝐫𝐬𝐭-𝐨𝐟-𝐢𝐭𝐬-𝐤𝐢𝐧𝐝 𝐟𝐥𝐮 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐮𝐬𝐢𝐧𝐠 𝐦𝐑𝐍𝐀 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 WASHINGTON — U.S. health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic. Moderna is seeking Food and Drug Administration approval of its new shot, dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season. https://www.ketv.com/article/moderna-mrna-flu-vaccine-mflusiva-fda-review/71625542
View on StockTwits ↗$ARCT The FDA policies are reverting back to normal. Moderna received unanimous recommendations for approval. UniQure is back on a pathway to approval. Chances are high that Arcturus Therapeutics will be next, with a BLA filing for KOSTAIVE.
View on StockTwits ↗$ARCT “On October 14, 2025, the FDA informed us that, although the FDA had previously agreed that our proposed data package could support a single-dose indication, upon further consideration it finds that additional data from a clinical endpoint efficacy study will be needed to align with the current COVID-19 vaccine regulatory framework requirements published in The New England Journal of Medicine in May 2025. The FDA’s sudden changes to regulatory requirements for COVID-19 vaccines have indefinitely delayed the U.S. BLA filing for KOSTAIVE.” https://ir.arcturusrx.com/static-files/d8a7d0b0-cc2a-4537-829e-5867f501098b
View on StockTwits ↗$ARCT FDA rejection of gene therapy overturned after Trump official ousted. Gene therapy company UniQure had another FDA meeting after Vinay Prasad’s exit. https://arstechnica.com/health/2026/06/truly-evil-fda-rejection-of-gene-therapy-overturned-after-trump-official-ousted/
View on StockTwits ↗$ARCT This makes ARCT's proprietary self-amplifying RNA (saRNA) platform known as STARR™ look so much better. The stock price should fly on Monday.
View on StockTwits ↗$ARCT Novo Nordisk has been hacked. Also, the gene therapy RNAi portfolio that they purchased for $3.3B is worthless, since they can't replicate the results. https://www.ransomware.live/id/Tm92byBOb3JkaXNrQGZ1bGNydW1zZWM
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.